• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
3 humongous healthcare stocks this week   2-7-14
 

3 humongous healthcare stocks this week 2-7-14

on

  • 8,115 views

Find out which healthcare stocks were the most humongous winners over the last week.

Find out which healthcare stocks were the most humongous winners over the last week.

Statistics

Views

Total Views
8,115
Views on SlideShare
805
Embed Views
7,310

Actions

Likes
0
Downloads
5
Comments
0

8 Embeds 7,310

http://www.fool.com 7037
http://m.fool.com 131
http://www.barchart.com 79
http://www.dailyfinance.com 55
http://cms.fool.com 4
http://www.chron.com 2
http://webcache.googleusercontent.com 1
http://10.140.30.109 1
More...

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849

3 humongous healthcare stocks this week   2-7-14 3 humongous healthcare stocks this week 2-7-14 Presentation Transcript

  • 3 Humongous Health-Care Stocks This Week
  • Seattle Seahawks fans weren’t the only ones dancing for joy this week. Here are three health-care stocks experiencing their own super celebrations. Source: Wikimedia Commons
  • Furiex Pharmaceuticals (Nasdaq: FURX) Shares of this drugmaker skyrocketed a whopping 137% this week.
  • Why Furiex rose so furiously • The company announced fantastic results from two midstage studies of eluxadoline. • The drug for diarrheapredominant irritable bowel syndrome met primary endpoints for both the FDA and EMA. • Furiex plans to file for regulatory approval in the second quarter.
  • Ohr Pharmaceutical (Nasdaq: OHRP) Shares of the biotech surged 30% higher for the week.
  • Why Ohr paddled its way so much higher • There were no big new developments this week. The Stock run-up is probably in anticipation of the company’s presentation at the BIO CEO & Investor Conference on Feb. 11. • There’s intense interest in wet AMD drug Squalamine.
  • Athenahealth (Nasdaq: ATHN) The cloud-based physicians’ software maker jumped 18% this week.
  • Why athenahealth is on Cloud Nine • It announced stellar Q4 results on Friday. • Adjusted earnings of $0.57 per share blew away analysts’ estimates of $0.44 per share. • Revenue is up an impressive 48% year-over-year to $171.6 million.
  • Best pick to stay humongous? • Furiex shows lots of potential. • It faces a potential market of 28 million patients in U.S. and Europe. • Limited treatment options are available for diarrhea-predominant irritable bowel syndrome. • It still must win regulatory approval – but its prospects look pretty good at this point.
  • Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!